These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9638104)

  • 41. Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH).
    Denti L; Pasolini G; Cortellini P; Sanfelici L; Benedetti R; Cecchetti A; Ferretti S; Banchini A; Ablondi F; Valenti G
    J Endocrinol Invest; 1999; 22(10 Suppl):70-1. PubMed ID: 10727053
    [No Abstract]   [Full Text] [Related]  

  • 42. [Finasteride: 10 years of clinical use. Systematic review of the literature].
    Jiménez Cruz JF; Quecedo Gutiérrez L; Del Llano Señarís J
    Actas Urol Esp; 2003 Mar; 27(3):202-15. PubMed ID: 12812118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia.
    Rich KT; Safranek S
    Am Fam Physician; 2008 Mar; 77(5):665-6. PubMed ID: 18350766
    [No Abstract]   [Full Text] [Related]  

  • 44. Saw palmetto extracts for benign prostatic hyperplasia.
    Segars LW
    J Fam Pract; 1999 Feb; 48(2):88-9. PubMed ID: 10037530
    [No Abstract]   [Full Text] [Related]  

  • 45. Finasteride and minoxidil for alopecia revisited.
    Med Lett Drugs Ther; 2005 Nov; 47(1222):95-6. PubMed ID: 16299452
    [No Abstract]   [Full Text] [Related]  

  • 46. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effects of finasteride on hematuria associated with benign prostatic hyperplasia: a meta-analysis].
    Jiang Y; Long YF
    Zhonghua Nan Ke Xue; 2010 Aug; 16(8):726-9. PubMed ID: 21090349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia.
    Isotalo T; Talja M; Hellström P; Perttilä I; Välimaa T; Törmälä P; Tammela TL
    BJU Int; 2001 Jul; 88(1):30-4. PubMed ID: 11446841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The evolution of the PCPT from clinical to molecular analyses.
    Hoque A
    Nat Clin Pract Oncol; 2006 Nov; 3(11):581. PubMed ID: 17080169
    [No Abstract]   [Full Text] [Related]  

  • 50. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks.
    Donohue JF; Hayne D; Karnik U; Thomas DR; Foster MC
    BJU Int; 2005 Dec; 96(9):1319-22. PubMed ID: 16287453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.
    Marberger MJ; Andersen JT; Nickel JC; Malice MP; Gabriel M; Pappas F; Meehan A; Stoner E; Waldstreicher J
    Eur Urol; 2000 Nov; 38(5):563-8. PubMed ID: 11096237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study].
    Sökeland J; Albrecht J
    Urologe A; 1997 Jul; 36(4):327-33. PubMed ID: 9340898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Finasteride in prolonged therapy of patients with benign prostatic hyperplasia].
    Mazo EB
    Urologiia; 2001; (3):20-2. PubMed ID: 11505535
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar.
    Byrnes CA; Morton AS; Liss CL; Lippert MC; Gillenwater JY
    Clin Ther; 1995; 17(5):956-69. PubMed ID: 8595647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Waxing and waning gynecomastia: an indication of noncompliant use of prescribed medication.
    Miller JA; Pramanik B; Gilhooly P
    South Med J; 1999 Jun; 92(6):615-7. PubMed ID: 10372857
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
    Lukkarinen O; Lehtonen T; Talja M; Lundstedt S; Tiitinen J; Taari K
    Ann Chir Gynaecol; 1999; 88(4):299-303. PubMed ID: 10661828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Using doxasosine and finasteride combination in the treatment of prostate adenoma].
    Bogdanov AB; Luk'ianov IV; Veliev EI
    Urologiia; 2006; (5):59-63. PubMed ID: 17444154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia.
    Sung JC; Curtis LH; Schulman KA; Albala DM
    J Urol; 2006 Mar; 175(3 Pt 1):1023-7. PubMed ID: 16469610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Finasteride: a steroid-unsparing drug?
    Persey M; Payne L; Webley M
    Rheumatology (Oxford); 1999 Mar; 38(3):285. PubMed ID: 10325672
    [No Abstract]   [Full Text] [Related]  

  • 60. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride.
    Foley SJ; Soloman LZ; Wedderburn AW; Kashif KM; Summerton D; Basketter V; Holmes SA
    J Urol; 2000 Feb; 163(2):496-8. PubMed ID: 10647664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.